Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine operating margin
Operating margin is operating income as a percentage of revenue.
Editas Medicine's operating margin for the twelve months ending Sep 30, 2026 was -151.7%. For fiscal 2025 it was -394.9%, against -777.2% the year before. The highest annual figure on record is -148.6% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -394.9% | +382.3 |
| FY2024 | Dec 31, 2024 | -777.2% | −560.7 |
| FY2023 | Dec 31, 2023 | -216.6% | +929.7 |
| FY2022 | Dec 31, 2022 | -1146.3% | −390.1 |
| FY2021 | Dec 31, 2021 | -756.1% | −607.5 |
| FY2020 | Dec 31, 2020 | -148.6% | +537.8 |
| FY2019 | Dec 31, 2019 | -686.4% | −330.3 |
| FY2018 | Dec 31, 2018 | -356.1% | +517.5 |
| FY2017 | Dec 31, 2017 | -873.6% | +732.0 |
| FY2016 | Dec 31, 2016 | -1605.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -234.3% | +91.2 |
| Q2 FY2026 | Jun 30, 2026 | -156.0% | +1284.5 |
| Q1 FY2026 | Mar 31, 2026 | -883.2% | +751.9 |
| Q4 FY2025 | Dec 31, 2025 | -31.3% | +120.9 |
| Q3 FY2025 | Sep 30, 2025 | -325.4% | +107323.7 |
| Q2 FY2025 | Jun 30, 2025 | -1440.6% | +12575.6 |
| Q1 FY2025 | Mar 31, 2025 | -1635.1% | +4267.2 |
| Q4 FY2024 | Dec 31, 2024 | -152.2% | −112.3 |
| Q3 FY2024 | Sep 30, 2024 | -107649.2% | −106709.1 |
| Q2 FY2024 | Jun 30, 2024 | -14016.2% | −12488.8 |
| Q1 FY2024 | Mar 31, 2024 | -5902.3% | −5385.0 |
| Q4 FY2023 | Dec 31, 2023 | -39.9% | +930.8 |
| Q3 FY2023 | Sep 30, 2023 | -940.1% | +136012.3 |
| Q2 FY2023 | Jun 30, 2023 | -1527.3% | −674.9 |
| Q1 FY2023 | Mar 31, 2023 | -517.3% | +232.2 |
| Q4 FY2022 | Dec 31, 2022 | -970.7% | −637.0 |
| Q3 FY2022 | Sep 30, 2022 | -136952.4% | −136319.0 |
| Q2 FY2022 | Jun 30, 2022 | -852.5% | +13765.2 |
| Q1 FY2022 | Mar 31, 2022 | -749.5% | +125.7 |
| Q4 FY2021 | Dec 31, 2021 | -333.7% | +243.2 |
| Q3 FY2021 | Sep 30, 2021 | -633.4% | −647.7 |
| Q2 FY2021 | Jun 30, 2021 | -14617.7% | −14326.1 |
| Q1 FY2021 | Mar 31, 2021 | -875.3% | −60.7 |
| Q4 FY2020 | Dec 31, 2020 | -576.9% | −255.9 |
| Q3 FY2020 | Sep 30, 2020 | 14.3% | +913.2 |
| Q2 FY2020 | Jun 30, 2020 | -291.6% | +1238.4 |
| Q1 FY2020 | Mar 31, 2020 | -814.5% | +696.4 |
| Q4 FY2019 | Dec 31, 2019 | -320.9% | +108.1 |
| Q3 FY2019 | Sep 30, 2019 | -898.9% | −786.9 |
| Q2 FY2019 | Jun 30, 2019 | -1530.0% | −992.1 |
| Q1 FY2019 | Mar 31, 2019 | -1511.0% | −707.3 |
| Q4 FY2018 | Dec 31, 2018 | -429.0% | +564.7 |
| Q3 FY2018 | Sep 30, 2018 | -112.0% | +313.8 |
| Q2 FY2018 | Jun 30, 2018 | -537.9% | +305.3 |
| Q1 FY2018 | Mar 31, 2018 | -803.6% | +3687.1 |
| Q4 FY2017 | Dec 31, 2017 | -993.8% | – |
| Q3 FY2017 | Sep 30, 2017 | -425.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -843.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -4490.8% | – |
See a number that looks wrong?